← Back to Search

real-time CGM for Type 2 Diabetes (TIGHT Trial)

N/A
Waitlist Available
Led By Judy Sibayan, MPH, CCRP
Research Sponsored by Jaeb Center for Health Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-10 days
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if using continuous monitoring of blood sugar levels can help hospitalized diabetes patients maintain better blood sugar levels without increasing the risk of low blood sugar. The study compares usual care with a new method that uses continuous monitoring of blood sugar levels. The goal is to see if the new method can improve patient outcomes, especially during infections like COVID-19. These monitoring systems have been shown to help manage blood sugar and improve safety in different healthcare settings.

Eligible Conditions
  • Type 2 Diabetes
  • Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-10 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4-10 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Co-: CGM-measured mean glucose (superiority)
Co-: CGM-measured percent time <54 mg/dL (non-inferiority)
Secondary study objectives
CGM Metrics by daytime only (06:00 AM to 00:00 AM)
CGM Metrics by nighttime only (00:00 AM to 06:00 AM)
Other study objectives
CGM metrics related to hyperglycemia
CGM metrics related to hypoglycemia
Glucose Variability

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intensive Target GroupExperimental Treatment1 Intervention
Intensive therapy with glucose target 90-130 mg/dL with real-time CGM
Group II: Standard Target GroupActive Control1 Intervention
Standard therapy with glucose target 140-180 mg/dL (ADA guidelines) and masked CGM
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
real-time CGM
2014
N/A
~200

Find a Location

Who is running the clinical trial?

DexCom, Inc.Industry Sponsor
144 Previous Clinical Trials
35,316 Total Patients Enrolled
Jaeb Center for Health ResearchLead Sponsor
157 Previous Clinical Trials
35,420 Total Patients Enrolled
Irl Hirsch, MDStudy ChairUniversity of Washington
3 Previous Clinical Trials
675 Total Patients Enrolled
~49 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top